Abdulmojeed Aishat O
Research Subjects
Abdulmojeed Aishat O has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Aisha Mukhtar Dodo
Community Health Service Department, National Primary Health Care Development Agency, Abuja, Nigeria
1 shared publication - Amina Ibrahim Shehu
Pharmacovigilance Department, National Agency for Food and Administration Control (NAFDAC), Abuja, Nigeria
1 shared publication - Aminat Suleman-Alabi
Department of Human Physiology, Federal University Lafia, Lafia, Nigeria
1 shared publication - Bankole Israel Adeyemi1 shared publication
- Chris Onyebuchi Ifediora
School of Medicine, Griffith University, Gold Coast Campus, Southport, Australia
1 shared publication Comfort Ohunene Mathew
1 shared publication
Latest Publications
- Open Access
- 4 June 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Comprehension, viewpoint and precautionary measures against covid-19 among pregnant women attending ante-natal care at a tertiary health facility in Abuja, Nigeria
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pregnant women are particularly vulnerable to COVID-19 due to physiological and immunological changes in pregnancy. Understanding their knowledge and preventive practices is essential for guiding maternal-health interventions. This study assessed the knowledge, perceptions, and adoption of preventive measures against COVID-19 among pregnant women attending antenatal care at the Federal Medical Centre (FMC), Jabi, Abuja. A descriptive cross-sectional study was conducted from July to September 2021 among pregnant women selected through multistage sampling. Using a structured, interviewer-administered questionnaire we obtained data on knowledge, perceptions and preventive practices from 120 women participated. Data was analyzed using SPSS version 28 and summarized as descriptive statistics. Awareness of COVID-19 was high (95.8%) among pregnant women. Most respondents demonstrated adequate knowledge of transmission and prevention, including hand hygiene (99.2%), avoidance of crowds (92.5%), and isolation measures (90.0%). Misconceptions persisted, particularly regarding breastfeeding. Only 35.0% agreed that COVID-19 positive mothers can safely breastfeed, while 42.5% were unsure. Vaccine willingness was moderate (54.2%), reflecting hesitancy despite overall good knowledge. We found high level of awareness and generally positive preventive attitudes toward COVID-19 among pregnant women, but gaps remain in breastfeeding knowledge and vaccine acceptance. Targeted health education and strengthened ANC counselling are needed to address misconceptions and support consistent adoption of preventive practices.
- 4 June 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessComprehension, viewpoint and precautionary measures against covid-19 among pregnant women attending ante-natal care at a tertiary health facility in Abuja, Nigeria
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pregnant women are particularly vulnerable to COVID-19 due to physiological and immunological changes in pregnancy. Understanding their knowledge and preventive practices is essential for guiding maternal-health interventions. This study assessed the knowledge, perceptions, and adoption of preventive measures against COVID-19 among pregnant women attending antenatal care at the Federal Medical Centre (FMC), Jabi, Abuja. A descriptive cross-sectional study was conducted from July to September 2021 among pregnant women selected through multistage sampling. Using a structured, interviewer-administered questionnaire we obtained data on knowledge, perceptions and preventive practices from 120 women participated. Data was analyzed using SPSS version 28 and summarized as descriptive statistics. Awareness of COVID-19 was high (95.8%) among pregnant women. Most respondents demonstrated adequate knowledge of transmission and prevention, including hand hygiene (99.2%), avoidance of crowds (92.5%), and isolation measures (90.0%). Misconceptions persisted, particularly regarding breastfeeding. Only 35.0% agreed that COVID-19 positive mothers can safely breastfeed, while 42.5% were unsure. Vaccine willingness was moderate (54.2%), reflecting hesitancy despite overall good knowledge. We found high level of awareness and generally positive preventive attitudes toward COVID-19 among pregnant women, but gaps remain in breastfeeding knowledge and vaccine acceptance. Targeted health education and strengthened ANC counselling are needed to address misconceptions and support consistent adoption of preventive practices.
- 11 January 2025
- Published by IK Press in Asian Journal of Microbiology and Biotechnology
- Vol. 10 (1) , 131-146
Progress and Prospects in HIV Vaccine Development: A Comprehensive Review
HIV/AIDS has been a disease condition affecting the entire world since its discovery in the 1980s, with over 38 million people in the globe living with the virus. Several attempts, research and funds have been channelled towards discovering a cure for HIV/AIDS yet no cure has been discovered. Considering the burden associated with the disease condition, having a vaccine to help control the spread will be a great approach in the course of achieving universal control coverage of the disease condition and an end to the disease over time. In this review we examined the progress, challenges, and future directions in HIV vaccine development and various types of vaccine candidates currently under investigation, highlighting key drug candidates that failed to provide protection against HIV such as PrEPVacc, HVTN 505, Uhambo (HVTN 702), Imbokodo (HVTN 705) and Mosaico (HVTN 706) as well as RV144 that provided 31.2% protection against HIV in a modified intent-to-treat analysis and those whose investigations are still in progress. The search for HIV Vaccine continues despite the modest success of some vaccines in clinical trials due to diversity in genetic nature of HIV, its ability to mutate rapidly, and the difficulty of eliciting a sustained immune response. Hence we also reviewed current approaches to improve on the success rate recorded by RV144.
- 11 January 2025
- Published by IK Press in Asian Journal of Microbiology and Biotechnology
- Vol. 10 (1) , 131-146
Progress and Prospects in HIV Vaccine Development: A Comprehensive Review
HIV/AIDS has been a disease condition affecting the entire world since its discovery in the 1980s, with over 38 million people in the globe living with the virus. Several attempts, research and funds have been channelled towards discovering a cure for HIV/AIDS yet no cure has been discovered. Considering the burden associated with the disease condition, having a vaccine to help control the spread will be a great approach in the course of achieving universal control coverage of the disease condition and an end to the disease over time. In this review we examined the progress, challenges, and future directions in HIV vaccine development and various types of vaccine candidates currently under investigation, highlighting key drug candidates that failed to provide protection against HIV such as PrEPVacc, HVTN 505, Uhambo (HVTN 702), Imbokodo (HVTN 705) and Mosaico (HVTN 706) as well as RV144 that provided 31.2% protection against HIV in a modified intent-to-treat analysis and those whose investigations are still in progress. The search for HIV Vaccine continues despite the modest success of some vaccines in clinical trials due to diversity in genetic nature of HIV, its ability to mutate rapidly, and the difficulty of eliciting a sustained immune response. Hence we also reviewed current approaches to improve on the success rate recorded by RV144.